Literature DB >> 24989239

Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis.

Cassandra N Spracklen, Caitlin J Smith, Audrey F Saftlas, Jennifer G Robinson, Kelli K Ryckman.   

Abstract

Published reports examining lipid levels during pregnancy and preeclampsia have been inconsistent. The objective of this meta-analysis was to test the association between preeclampsia and maternal total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and triglyceride levels measured during pregnancy. We conducted a systematic search for studies published between the index date until July 2013 reporting maternal lipid levels in women with preeclampsia and normotensive pregnant women. Seventy-four studies met all eligibility criteria and were included in the meta-analysis. Weighted mean differences in lipid levels were calculated using a random-effects model. Statistical heterogeneity was investigated using the I(2) statistic. Meta-regression was used to identify sources of heterogeneity. Preeclampsia was associated with elevated total cholesterol, non-HDL-C, and triglyceride levels, regardless of gestational age at the time of blood sampling, and with lower levels of HDL-C in the third trimester. A marginal association was found with LDL-C levels. Statistical heterogeneity was detected in all analyses. Meta-regression analyses suggested that differences in body mass index (weight (kg)/height (m)(2)) across studies may be partially responsible for the heterogeneity in the triglyceride and LDL-C analyses. This systematic review and meta-analysis demonstrates that women who develop preeclampsia have elevated levels of total cholesterol, non-HDL-C, and triglycerides during all trimesters of pregnancy, as well as lower levels of HDL-C during the third trimester.
© The Author 2014. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  body mass index; cholesterol; hyperlipidemia; hypertriglyceridemia; meta-analysis; preeclampsia; systematic review; triglycerides

Mesh:

Substances:

Year:  2014        PMID: 24989239      PMCID: PMC4565654          DOI: 10.1093/aje/kwu145

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  87 in total

Review 1.  Immunology of pre-eclampsia.

Authors:  Christopher W G Redman; Ian L Sargent
Journal:  Am J Reprod Immunol       Date:  2010-03-23       Impact factor: 3.886

2.  Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia.

Authors:  J T Murai; E Muzykanskiy; R N Taylor
Journal:  Metabolism       Date:  1997-08       Impact factor: 8.694

3.  Oxidized-LDL levels in normal and pre-eclamptic pregnancies: contribution of LDL particle size.

Authors:  Luís Belo; Alice Santos-Silva; Muriel Caslake; Luís Pereira-Leite; Alexandre Quintanilha; Irene Rebelo
Journal:  Atherosclerosis       Date:  2005-08-01       Impact factor: 5.162

Review 4.  Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.

Authors:  John Deanfield; Ann Donald; Claudio Ferri; Cristina Giannattasio; Julian Halcox; Sean Halligan; Amir Lerman; Giuseppe Mancia; James J Oliver; Achille C Pessina; Damiano Rizzoni; Gian Paolo Rossi; Antonio Salvetti; Ernesto L Schiffrin; Stefano Taddei; David J Webb
Journal:  J Hypertens       Date:  2005-01       Impact factor: 4.844

Review 5.  Redefining preeclampsia using placenta-derived biomarkers.

Authors:  Anne Cathrine Staff; Samantha J Benton; Peter von Dadelszen; James M Roberts; Robert N Taylor; Robert W Powers; D Stephen Charnock-Jones; Christopher W G Redman
Journal:  Hypertension       Date:  2013-03-04       Impact factor: 10.190

6.  Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia.

Authors:  H Uzun; A Benian; R Madazli; M A Topçuoğlu; S Aydin; M Albayrak
Journal:  Gynecol Obstet Invest       Date:  2005-07-26       Impact factor: 2.031

Review 7.  Pre-diabetes, metabolic syndrome, and cardiovascular risk.

Authors:  Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

8.  Insulin resistance and C-reactive protein in preeclampsia.

Authors:  Milan Stefanović; Predrag Vukomanović; Mileva Milosavljević; Ranko Kutlesić; Jasmina Popović; Aleksandra Tubić-Pavlović
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

9.  Antioxidant activity and lipid peroxidation in preeclampsia.

Authors:  Usha Adiga; Vivian D'souza; Asha Kamath; Nandini Mangalore
Journal:  J Chin Med Assoc       Date:  2007-10       Impact factor: 2.743

Review 10.  Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis.

Authors:  Morven Caroline Brown; Kate Elizabeth Best; Mark Stephen Pearce; Jason Waugh; Stephen Courtenay Robson; Ruth Bell
Journal:  Eur J Epidemiol       Date:  2013-02-09       Impact factor: 8.082

View more
  62 in total

1.  Physical Activity During Pregnancy and Subsequent Risk of Preeclampsia and Gestational Hypertension: A Case Control Study.

Authors:  Cassandra N Spracklen; Kelli K Ryckman; Elizabeth W Triche; Audrey F Saftlas
Journal:  Matern Child Health J       Date:  2016-06

2.  Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia.

Authors:  Caitlin J Smith; Audrey F Saftlas; Cassandra N Spracklen; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2015-05-23       Impact factor: 2.689

Review 3.  Biosensors for Detection of Human Placental Pathologies: A Review of Emerging Technologies and Current Trends.

Authors:  Jia Liu; Babak Mosavati; Andrew V Oleinikov; E Du
Journal:  Transl Res       Date:  2019-05-20       Impact factor: 7.012

4.  Spectrum of Factors Triggering Endothelial Dysfunction in PIH.

Authors:  Visala Sree Jammalamadaga; Philips Abraham
Journal:  J Clin Diagn Res       Date:  2016-12-01

5.  Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers.

Authors:  K M Renault; E M Carlsen; S Hædersdal; L Nilas; N J Secher; J Eugen-Olsen; D Cortes; S F Olsen; T I Halldorsson; K Nørgaard
Journal:  Int J Obes (Lond)       Date:  2017-01-17       Impact factor: 5.095

6.  Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts.

Authors:  G S Stødle; G B Silva; L H Tangerås; L M Gierman; I Nervik; U E Dahlberg; C Sun; M H Aune; L C V Thomsen; L Bjørge; A-C Iversen
Journal:  Clin Exp Immunol       Date:  2018-04-23       Impact factor: 4.330

7.  Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia.

Authors:  Cassandra N Spracklen; Audrey F Saftlas; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2014-12-17       Impact factor: 2.689

8.  Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

9.  The associations between early pregnancy lipid profiles and pregnancy outcomes.

Authors:  C Wang; W Zhu; Y Wei; R Su; H Feng; E Hadar; M Hod; H Yang
Journal:  J Perinatol       Date:  2016-10-27       Impact factor: 2.521

10.  Dyslipidemia and the role of adipose tissue in early pregnancy in the BPH/5 mouse model for preeclampsia.

Authors:  Dorien Reijnders; Kelsey N Olson; Chin-Chi Liu; Kalie F Beckers; Sujoy Ghosh; Leanne M Redman; Jenny L Sones
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-04-17       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.